Opioid‐induced inhibition of the human 5‐HT and noradrenaline transporters in vitro: link to clinical reports of serotonin syndrome
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Background and Purpose: Opioids may inhibit the 5‐HT transporter (SERT) and the noradrenaline transporter (NET). NET inhibition may contribute to analgesia, and SERT inhibition or interactions with 5‐HT receptors may cause serotonergic toxicity. However, the effects of different opioids on the human SERT, NET and 5‐HT receptors have not been sufficiently studied. Experimental Approach: We determined the potencies of different opioids to inhibit the SERT and NET in vitro using human transporter‐transfected HEK293 cells. We also tested binding affinities at 5‐HT 1A, 5‐HT 2A and 5‐HT 2C receptors. Additionally, we assessed clinical cases of the serotonin syndrome associated with each opioid reported by PubMed and a World Health Organization database. Key Results: Dextromethorphan, l(R)‐methadone, racemic methadone, pethidine, tramadol and tapentadol inhibited the SERT at or close to observed drug plasma or estimated brain concentrations in patients. Tapentadol was the most potent NET inhibitor. Pethidine, tramadol, l(R)‐methadone, racemic methadone, dextromethorphan and O‐desmethyltramadol also inhibited the NET. 6‐Monoacetylmorphine, buprenorphine, codeine, dihydrocodeine, heroin, hydrocodone, hydromorphone, morphine, oxycodone and oxymorphone did not inhibit the SERT or NET. Fentanyl interacted with 5‐HT 1A receptors and methadone, pethidine and fentanyl with 5‐HT 2A receptors, in the low micromolar range. Opioids most frequently associated with the serotonin syndrome are tramadol, fentanyl, tapentadol, oxycodone, methadone and dextromethorphan. Conclusions and Implications: Some synthetic opioids interact with the SERT and NET at potentially clinically relevant concentrations. SERT inhibition by tramadol, tapentadol, methadone, dextromethorphan and pethidine may contribute to the serotonin syndrome. Direct effects on 5‐HT 1A and/or 5‐HT 2A receptors could be involved with methadone and pethidine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Boyer, E. W., & Shannon, M. (2005) · New England Journal of Medicine · doi:10.1056/nejmra041867 · Cited by 1,821 · cited 1×
“SERT inhibition may have analgesic effects but may also increase the risk of 5-HT toxicity (Boyer and Shannon, 2005).”
BackgroundPharmacological profile of antidepressants and related compounds at human monoamine transporters
Tatsumi, M., Groshan, K., Blakely, R. D., & Richelson, E. (1997) · European Journal of Pharmacology · doi:10.1016/s0014-2999(97)01393-9 · Cited by 939
The use of ATP bioluminescence as a measure of cell proliferation and cytotoxicity
Crouch, S. P. M., Kozlowski, R., Slater, K. J., & Fletcher, J. (1993) · Journal of Immunological Methods · doi:10.1016/0022-1759(93)90011-u · Cited by 926
THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: g protein-coupled receptors
Alexander, S. P., Christopoulos, A., Davenport, A. P., Kelly, E., Marrion, N. V., Peters, J. A., Faccenda, E., Harding, S. D., Pawson, A. J., Sharman, J. L., et al. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13878 · Cited by 588 · cited 1×
“…ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Southan et al., 2016), and are permanently archived in the Concise Guide to PHARMACOLOGY 2017/18 (Alexander et al., 2017a,b).”
Method
Cited by
Designer drugs: mechanism of action and adverse effects
Luethi, D., & Liechti, M. E. (2020) · Archives of Toxicology · doi:10.1007/s00204-020-02693-7 · Cited by 262
Self-citationTreating Chronic Pain: An Overview of Clinical Studies Centered on the Buprenorphine Option
Davis, M. P., Pasternak, G., & Behm, B. (2018) · Drugs · doi:10.1007/s40265-018-0953-z · Cited by 138
The anaesthetist, opioid analgesic drugs, and serotonin toxicity: A mechanistic and clinical review
Baldo, B. A., & Rose, M. A. (2020) · British Journal of Anaesthesia · doi:10.1016/j.bja.2019.08.010 · Cited by 133
Fava, M., Stahl, S., Pani, L., De Martin, S., Pappagallo, M., Guidetti, C., Alimonti, A., Bettini, E., Mangano, R. M., Wessel, T., et al. (2022) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2021.21020197 · Cited by 83
Roussin, A., Soeiro, T., Fouque, C., Jouanjus, E., Frauger, E., Fouilhé, N., Mallaret, M., Micallef, J., Lapeyre‐Mestre, M., & the French Addictovigilance Network (FAN) (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15323 · Cited by 38
“Tramadol is an atypical opioid analgesic as it also inhibits the reuptake of serotonin and norepinephrine.(6) The metabolite M1 of tramadol (O-desmethyl tramadol) produced in the liver by the polymorphic CYP2D6 has a 200–500 higher affinity for mu-opioid receptor and a more potent activity at this receptor than its pa…”
Background
Metadata
- Authors
- Rickli, A., Liakoni, E., Hoener, M. C., & Liechti, M. E.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2018-01-06
- Volume
- 175
- Issue
- 3
- Pages
- 532-543
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W2772873931
- Cited by
- 104
- References
- 4
- FWCI
- 4.11
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Opioid‐induced inhibition of the human 5‐HT and noradrenaline transporters in vitro: link to clinical reports of serotonin syndrome. https://app.cochat.ai/papers/10.1111/bph.14105
- The paper
- Rickli, A., Liakoni, E., Hoener, M. C., & Liechti, M. E. (2018). Opioid‐induced inhibition of the human 5‐HT and noradrenaline transporters in vitro: link to clinical reports of serotonin syndrome. British Journal of Pharmacology. https://doi.org/10.1111/bph.14105
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.